Celea Therapeutics Appoints Paul Audhya as Medical Chief
The Boston-based firm adds the industry veteran to lead clinical development and strategy for its antifibrotic program.
Updated on Oct. 29, 2026 in People
Live Poll
Do you trust executive leadership changes to improve long-term outcomes for new medical treatments?
Celea Therapeutics has named Paul Audhya, an MD and MBA with three decades of experience, as its new Chief Medical Officer. The appointment aims to bolster the leadership team at the Boston biopharmaceutical firm as it advances through key clinical milestones.
Why it matters
This leadership expansion is designed to support the next phase of company growth for the clinical-stage biotech. The move aligns with the firm's strategic focus on pushing its lead investigational therapy through advanced testing.
Celea Therapeutics secured $180 million in financing during July 2026 to support its operations. Paul Audhya joins the company with three decades of clinical development experience.
The players
Paul Audhya
He is the new Chief Medical Officer at Celea Therapeutics and previously served in the same role at KalVista Pharmaceuticals, Inc.
Celea Therapeutics
Based in Boston, this clinical-stage biopharmaceutical company spun off from PureTech Health to develop new therapies.
The details
Audhya will oversee the clinical development and medical strategy for deupirfenidone, an oral antifibrotic therapy. The company, which spun off from PureTech Health, is currently conducting the Phase 3 SURPASS-IPF trial for idiopathic pulmonary fibrosis.
Timeline
July 2026: Celea Therapeutics closed $180 million in financing.
October 29, 2026: Paul Audhya was appointed as Chief Medical Officer.
Market Landscape
The appointment of a new medical chief to oversee the Phase 3 SURPASS-IPF trial signals a strategic focus on moving late-stage assets toward potential commercialization. This leadership shift highlights the competitive nature of the biopharmaceutical sector in Boston as firms scale their executive teams.
The leadership change serves as an internal operational move rather than an immediate change to consumer-facing prices or product availability. Patients and stakeholders should look to upcoming clinical trial updates for indicators of future treatment options.
The takeaway
The addition of an experienced executive indicates a transition from early-stage research to advanced clinical development for the firm. Investors and stakeholders should monitor how this new leadership shapes the company's progress through the ongoing Phase 3 trial.
Further reading
For more on industry leadership changes, visit the Boston People section.
Live Poll
Do you trust executive leadership changes to improve long-term outcomes for new medical treatments?
